Correlation Between Longboard Pharmaceuticals and Theriva Biologics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Longboard Pharmaceuticals and Theriva Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Longboard Pharmaceuticals and Theriva Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Longboard Pharmaceuticals and Theriva Biologics, you can compare the effects of market volatilities on Longboard Pharmaceuticals and Theriva Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Longboard Pharmaceuticals with a short position of Theriva Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Longboard Pharmaceuticals and Theriva Biologics.

Diversification Opportunities for Longboard Pharmaceuticals and Theriva Biologics

-0.4
  Correlation Coefficient

Very good diversification

The 3 months correlation between Longboard and Theriva is -0.4. Overlapping area represents the amount of risk that can be diversified away by holding Longboard Pharmaceuticals and Theriva Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Theriva Biologics and Longboard Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Longboard Pharmaceuticals are associated (or correlated) with Theriva Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Theriva Biologics has no effect on the direction of Longboard Pharmaceuticals i.e., Longboard Pharmaceuticals and Theriva Biologics go up and down completely randomly.

Pair Corralation between Longboard Pharmaceuticals and Theriva Biologics

Given the investment horizon of 90 days Longboard Pharmaceuticals is expected to generate 0.75 times more return on investment than Theriva Biologics. However, Longboard Pharmaceuticals is 1.33 times less risky than Theriva Biologics. It trades about 0.21 of its potential returns per unit of risk. Theriva Biologics is currently generating about -0.14 per unit of risk. If you would invest  2,758  in Longboard Pharmaceuticals on September 17, 2024 and sell it today you would earn a total of  3,240  from holding Longboard Pharmaceuticals or generate 117.48% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy86.15%
ValuesDaily Returns

Longboard Pharmaceuticals  vs.  Theriva Biologics

 Performance 
       Timeline  
Longboard Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Solid
Over the last 90 days Longboard Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly unfluctuating basic indicators, Longboard Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.
Theriva Biologics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Theriva Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Longboard Pharmaceuticals and Theriva Biologics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Longboard Pharmaceuticals and Theriva Biologics

The main advantage of trading using opposite Longboard Pharmaceuticals and Theriva Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Longboard Pharmaceuticals position performs unexpectedly, Theriva Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Theriva Biologics will offset losses from the drop in Theriva Biologics' long position.
The idea behind Longboard Pharmaceuticals and Theriva Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance